This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.”
These results raise safety and efficacy concerns. “Ensuring accurate CBD dosage labelling is important for consumer safety and efficacy,” said Dr. Guy Setton , CEO of GemmaCert Ltd. Media Contact: Hadas Weizman hadas@marcomm.co.il +972(0)54-6077622. TEL AVIV, Israel , Feb.
WHAT: During the session, “ Cannabis Moves Toward the Mainstream ,” Nielsen will share IRI and BDSA’s predictions for mainstream market opportunities, cannabis ingredients, product development, labeling and safety. . . WHO: Jennifer Pelino, executive vice president, omnichannel media, IRI. . WHEN: Sept. 21, 2021, at 11:00 a.m.
If you feel like you’ve been catching a lot of Delta-8 THC content in the media lately, those aren’t just your social media apps hacking your brain. Hemp-derived Delta-8 THC is having a big moment in 2021 in terms of popularity and, most recently, in terms of concerns over legality, safety, and accuracy.
hemp farmers are denied profitable markets for their crops, while unregulated products continue to proliferate, with no safeguards for public health and safety. With regard to adding CBD to food and beverages, FDA maintains that the data currently available raises safety concerns and encourages parties to share relevant information with FDA.
The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. This includes ongoing work to obtain and evaluate information to address outstanding questions related to the safety of CBD products, while maintaining the agency’s rigorous public health standards.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.
I’m excited to join the Travelers Institute for a data-driven discussion,” said Wasserman. With new census data, control of Congress on a knife-edge and redistricting just ahead, there couldn’t be a better time to dive into the numbers.”. Media: Sperry Mylott, 860.277.5075. 22 – “High Risk? smylott@travelers.com.
The FDA is aware of media reports of delta-8 THC products getting consumers “high.” Thus, historical use of cannabis cannot be relied upon in establishing a level of safety for these products in humans. Findings based on NPDS data do not necessarily reflect the opinions of AAPCC. exposures to any substance(s).
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Recent data suggest the US science knowledge is about the global average.
The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safetydata will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. and are difficult to predict. cbdMD, Inc. John Weston. Director of Investor Relations.
On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is collecting data to fill these gaps. The public hearing attracted over 100 speakers and 2000 participants.
Here’s how the 282 acres stacked up by license type: Figuring out cultivation size nationally is probably more art than science given the data gaps that exist. Currently, Oklahoma has 7,754 licenses according to the Cannabiz Media License Database – but there is no limit to how much cannabis an Oklahoma cultivator can grow.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61
Ed Keating is a co-founder of Cannabiz Media and oversees the company’s data research and government relations efforts. Ed has managed product, marketing, and sales while overseeing complex multijurisdictional product lines in the securities, corporate, UCC, safety, environmental, and human resource markets. .
In his statement, Commissioner Hahn noted that the FDA was working on: 1) continuing to educate the public on the risks of CBD; 2) seeking reliable data on the safety and benefits of CBD, including opening the public docket on the matter; and 3) monitoring the marketplace for the sale and marketing of unapproved drugs.
Safetydata is limited, and testing for CRC contamination is missing—even in legalization states. Many legal and illicit hashmakers now use a ‘color remediation column’—often a steel cylinder (column) packed with a filtration media like sand—during extraction to filter impurities. What is CRC tech? How safe is CRC hash?
The Financial Times explains: “The excitement over cannabis in Colombia has reached fever pitch with some local media reports suggesting the country could supply two-fifths of the world’s marijuana and earn more from it than it does from coal or cut flowers. The checklist is endless, but every box needs to be marked.
The authors added that in spite of the growing availability and diversity of alternative cannabinoid products like artisanal CBD—as opposed to pharmaceutical CBD—existing studies assessing their efficacy and/or safety are extremely rare. The majority of patients (74%) were Caucasian and more than half (55%) identified as female.
I mean duh, with social media, bosses that don’t understand you have a life and the new Bob Dylan documentary on Netflix – how can anyone doze off and dream anymore? And who doesn’t feel that dark cloud of stress, anxiety and drag get bigger when they’re tossing and turning all night? So what’s next?
These results raise safety and efficacy concerns. “Ensuring accurate CBD dosage labelling is important for consumer safety and efficacy,” said Dr. Guy Setton , CEO of GemmaCert Ltd. Media Contact: Hadas Weizman hadas@marcomm.co.il +972(0)54-6077622. TEL AVIV, Israel , Feb.
The Center for Disease Control (CDC), the federal agency that is on the front lines for any threat to public health, works closely with FDA and state health departments to gather data and then communicates risk to the public. When a product has been widely distributed, the news media is used to reach large numbers of people.
And as the epidemic dragged on, news reports covered a notable dip in vape sales, understandably as consumers took a slight step back from vaping until safety could be assured. Since then, data has shown that vaping cannabis sales have stabilized, and even increased market share in a number of states. the week of August 19 to 24.3%
The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”. “In
The findings in this report point to policies and practices that promote and preserve public health and safety, while allowing legal businesses to compete.”. “We are pleased to release this report that highlights the successful launch of Maine’s adult use market,” said OCP Director Erik Gundersen. “The
The 2022-23 budget and accompanying tax reform bill will provide significant and immediate relief to cannabis businesses, support equity operators, strengthen enforcement tools against illegal cannabis operators, and protect youth, environmental, and public safety programs funding. Supporting equity. million dollars to-date.
Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.
CP: I’m going to say yes and it’s hard to tie this together, but there’s actually some really good animal, and a little bit of human data to support this. I postulate that that is correlated to our endocannabinoid system, which good data is now suggesting, is dysregulated in metabolic syndrome: obesity, diabetes, heart disease.
The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In
In the latest episode of the Cannacurio Podcast from Cannabiz Media, my co-host, Amanda Guerrero, and I discuss license updates coming to the Cannabiz Media License Database, including Oregon cannabis licenses, Louisiana CBD licenses, and Pennsylvania, Ohio, Montana and South Carolina hemp licenses. Ed Keating : Hi Amanda.
For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g.,
Ed Keating is a co-founder of Cannabiz Media and oversees the company’s data research and government relations efforts. Ed has managed product, marketing, and sales while overseeing complex multijurisdictional product lines in the securities, corporate, UCC, safety, environmental, and human resource markets. .
Health and Safety. The safety of our community is of utmost importance to ensure a constructive live event that advances the dynamic advanced design and manufacturing sectors that rely on IME West for new business partnerships and continued education.”. Media Contacts Lauren Lloyd. IMEWest #DiscoverEngineerBuild. PR Director.
Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. FDA is the government agency that ensures the safety and quality of foods, drugs, cosmetics, and other like products marketed in the United States. CBD Legal and Safety Issues An FDA report presented to the U.S.
AJEM’s mission is to create, collect, and disseminate credible cannabis research data. United States Food and Drug Administration Center for Food Safety and Applied Nutrition. Scientific data and information about products containing cannabis or cannabis-derived compounds. link] media/128593/download. Cannabis Law J.
Mycotoxins are contaminants that licensees are required to screen for to uphold public health, safety, and welfare. Mycotoxins are contaminants that licensees are required to screen for to uphold public health, safety, and welfare. There are currently no ISO-accredited Independent Testing Laboratories located on Nantucket.
In the latest episode of the Cannacurio Podcast from Cannabiz Media, my co-host, Amanda Guerrero, and I discuss speak with Lews Koski, Chief Operating Officer of Metrc , a leading seed-to-sale track-and-trace technology company for the cannabis and hemp industries. Amanda Guerrero: Welcome to the Cannacurio Podcast, powered by Cannabiz Media.
Ability to meet the overall health needs of qualified patients and safety of the public. Measure 1, Security plan: The applicant shall provide an acceptable safety and security plan, including staffing and site plan, and a detailed description of proposed security and safety measures, which demonstrates compliance with the rules at N.J.A.C.
It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. Some states require mandatory warning statements in advertisements for medical cannabis. a playground, recreation centre, library or public park.
Wurzer agreed, saying “I don’t have a ton of good data on this.”. For convenience and fire safety, flick that BIC. Mitchell Colbert is a freelance journalist who has written for Cannabis Now, Hemp Magazine, Green Flower Media, High Times, the Wine Industry Advisor, and other cannabis- and alcohol-focused publications.
In the latest episode of the Cannacurio Podcast from Cannabiz Media, my co-host, Amanda Guerrero, and I discuss speak with Robert Mohr, Cannabis Channel Manager, and Haley Hayes, Sales Executive, from PeopleGuru , a cloud-based and cannabis-friendly HR payroll, human capital management, and technology provider. Ed Keating: I don’t know.
These studies incorporate data from more than 714 patients with either LGS or Dravet syndrome, two rare forms of epilepsy with high morbidity and mortality rates, which place a significant burden on families and caregivers. All investor and media enquiries. media enquiries. media enquiries. publicrelations@gwpharm.com.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content